Form 4 for GILD Gilead Sciences
Accepted 2024-03-11 00:00:00 ET · period of report 2024-03-10 · accession 0001127602-24-009546 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-03-11 | 2024-03-10 | GILD | Parsey Merdad | Chief Medical Off | M - OptEx | — | +10.4K | 103.1K | +11% | — |
| D | 2024-03-11 | 2024-03-10 | GILD | Parsey Merdad | Chief Medical Off | F - Tax | $75.12 | -4,803 | 98.3K | -5% | -$360.8K |
| DM | 2024-03-11 | 2024-03-10 | GILD | Parsey Merdad | Chief Medical Off | A - Grant | $0.00 | +107.3K | 89.7K | New | $0 |
| DM | 2024-03-11 | 2024-03-10 | GILD | Parsey Merdad | Chief Medical Off | M - OptEx | — | -10.4K | 30.6K | -25% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-10 | M | A | 3,455 | — | 96,161 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 2 | Common | Common Stock | 2024-03-10 | F | D | 4,803 | $75.12 | 98,304 | D | — | — | |
| 3 | Common | Common Stock | 2024-03-10 | M | A | 6,946 | — | 103,107 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 4 | Derivative | Restricted Stock Unit | 2024-03-10 | A | A | 17,640 | — | 48,214 | D | — · — to — | 17,640 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F3) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 5 | Derivative | Non-qualified Stock Option (Right to Buy) | 2024-03-10 | A | A | 89,660 | $0.00 | 89,660 | D | $75.12 · — to 2034-03-10 | 89,660 Common Stock | (F4) The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 6 | Derivative | Restricted Stock Unit | 2024-03-10 | M | D | 3,455 | — | 37,520 | D | — · — to — | 3,455 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. |
| 7 | Derivative | Restricted Stock Unit | 2024-03-10 | M | D | 6,946 | — | 30,574 | D | — · — to — | 6,946 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F3) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. |